Surge in Adoption of Next-Gen Non-Invasive DNA Tests for High-Risk Pregnancies to Drive NIPT Market
By LabMedica International staff writers Posted on 07 Oct 2022 |
The global non-invasive prenatal testing (NIPT) market is projected to register a CAGR of 14.8% between 2022 and 2031 to reach USD 8.4 billion by the end of 2031, driven by an increase in the prevalence of Turners' syndrome and Down's syndrome among newborn babies, as well as a surge in the adoption of next-gen non-invasive DNA tests in high-risk pregnancies.
These are the latest findings of Transparency Market Research (Wilmington, DE, USA), a global market research company.
There has been a rise in cases of Down's syndrome and Turners' syndrome among newborn babies globally which is driving demand in the NIPT market. The popularity of NIPT has been increasing in recent years owing to the ability of this procedure to provide precise test results within a short duration. As a result, the growing adoption of testing is creating lucrative growth prospects for the NIPT market.
Additionally, governments in several countries are implementing favorable policies to provide complete reimbursement of NIPT in the second trimester, resulting in a rise in the adoption of such tests. Moreover, regulatory authorities in several countries are focusing on offering reimbursement for different tests, including non-invasive prenatal tests for chromosomal health issues such as Down's syndrome. These efforts are expected to drive sales of the global NIPT market.
Going forward, growing preference among healthcare professionals for performing next-gen non-invasive DNA tests for high-risk pregnancies is expected to drive sales of the NIPT market. Further, the increasing trend of delaying pregnancy among couples is anticipated to fuel market growth. Also, a surge in the prevalence of pregnancy-related problems in the second or third trimester is likely to contribute to the market growth.
Geographically, the North American NIPT market is anticipated to register the strongest growth during the forecast period owing to an increase in diagnosis and treatment of trisomy health issues, the presence of several key players, and existence of a well-established healthcare infrastructure in the U.S. The Asia Pacific NIPT market is expected to expand at a fast pace due to an increase in maternal age in the region, which can lead to a rise in cases of chromosomal aneuploidies among babies.
Related Links:
Transparency Market Research
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics